Drug Profile
EGFRvIII-directed CAR T-cell tharapy - Novartis/University of Pennsylvania
Alternative Names: CAR-T-EGFRvIIILatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Novartis; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in USA (IV, Infusion)